Free keyword(s): asma ; densidad mineral ósea ; crecimiento Tipo de Trabajo Académico: Trabajo Fin de Master
Notas: Today, it is known that the systemic effects of inhaled glucocorticoids, such as suppression of the hypothalamic-pituitary-adrenal axis are less pronounced than with oral corticosteroids, however, there are still few studies on the adverse effects of treatment administration as chronic. The objectives of the study were to assess whether there is involvement in bone mineral density, height, weight, in children with continuous treatment with inhaled corticosteroids and whether there are differences between steroid use and the diagnostic methods used. The study was descriptive-analytical cross-sectional. Children 2-15 years with a diagnosis of bronchial asthma with prolonged treatment with inhaled corticosteroids who attended at Miguel Servet’s Hospital between November 2011 and June 2012 participated. The records noting: starting day of inhaled corticosteroids, type of steroid, dose previously received, height, age, weight, BMI, pubertal stage. Later all of them were bone density measurement using ultrasound (US) methods and subsequently DXA lumbar by family consent. There was no involvement of bone mineral density and changes in terms of height and weight in children with continuous treatment with inhaled corticosteroids. No significant difference was found between budesonide versus fluticasone regarding alteration of bone mineral density. We found a weak positive correlation between the values of Z-score of ultrasound versus DXA. In conclusion, the prolonged use of mild to moderate doses of inhaled corticosteroids in asthma patients no influence on the decrease in children’s bone mass.